---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009949"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:37:06.744010+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ensysce Q1 net loss narrows to $1.9M; PF614-MPAR trial Part 1 completes, patent allowed for OUD candidate

## Summary
- Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.
- Cash $3.1M at March 31, 2025; subsequent warrant exercises raised $2.2M gross.
- PF614-MPAR-102 Part 1 confirmed overdose protection at higher doses; Parts 2 & 3 enrollment underway.
- U.S. patent allowed for PF9001 (OUD) covering composition of matter and method of use.
- Federal grant funding increased to $1.3M from $0.3M, supporting MPAR and OUD programs.

## SEC filing metadata
- accession: 0001641172-25-009949
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/0001641172-25-009949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000164117225009949/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009949
- JSON: https://secwatch.observer/filing/0001641172-25-009949.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.